^
Association details:
| Biomarker: | EGFRvIII mutation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Excerpt:
For PFS, the presence of EGFRvIII mutant was correlated with poor survival in the erlotinib arm (P = .003)...
DOI:
10.1200/JCO.2008.17.5984
Trial ID: